EGFR and neoplasm: Cluster B was characterized by over-represented mutations in established or candidate tumour suppressor genes such as STK1144 and RASSF845 and oncogenes such as SKP246 and FAM83B, which participates in the EGFR signalling pathway and may activate both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signalling cascade47.